“The first patient has been dosed in a Phase I trial of Stablepharma’s tetanus-diphtheria vaccine, which does not need to be refrigerated.

The vaccine candidate, SPVX02, is completely stable at room temperature, and in testing was fully potent after three cycles of extreme temperature fluctuations ranging from -20°C to 40°C.  The candidate has been developed to withstand these temperatures through the company’s StablevaX technology.

In what is being branded a ‘world-first’, the first patient in the trial of SPVX02 was dosed earlier this month at a National Health Service (NHS) site in the UK. The vaccine doses of SPVX02 being used in the Phase I study also have an 18-month shelf life.”

From Clinical Trials Arena.